THE B4GALT1 EXPRESSION IS PROGNOSTIC AND PREDICTIVE FOR POSTOPERATIVE ADJUVANT CHEMOTHERAPY BENEFIT IN PATIENTS WITH MUSCLE‐INVASIVE BLADDER CANCER: MP58‐08

Huyang Xie,Yu Zhu,Zewei Wang,Qiang Fu,Jiejie Xu,Dingwei Ye
DOI: https://doi.org/10.1016/j.juro.2017.02.1803
IF: 7.6
2017-01-01
The Journal of Urology
Abstract:You have accessJournal of UrologyBladder Cancer: Invasive V1 Apr 2017MP58-08 THE B4GALT1 EXPRESSION IS PROGNOSTIC AND PREDICTIVE FOR POSTOPERATIVE ADJUVANT CHEMOTHERAPY BENEFIT IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER Huyang Xie, Yu Zhu, Zewei Wang, Qiang Fu, Jiejie Xu, and Dingwei Ye Huyang XieHuyang Xie More articles by this author , Yu ZhuYu Zhu More articles by this author , Zewei WangZewei Wang More articles by this author , Qiang FuQiang Fu More articles by this author , Jiejie XuJiejie Xu More articles by this author , and Dingwei YeDingwei Ye More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.1803AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Beta-1, 4-Galactosyltransferase gene (B4GALT) family consists of seven members, which encode corresponding enzymes known as type II membrane-bound glycoproteins. These enzymes catalyze the biosynthesis of different glycoconjugates and saccharide structures, and have been recognized to be involved in various diseases. In this study, we sought to determine the bladder cancer cell's B4GALT1 expression and its association with the infiltrated CD8+ T cell number, together with the association with the patients' outcome, as well as the benefit from adjuvant chemotherapy in patients with muscle-invasive bladder cancer (MIBC). METHODS We recruited 201 and 172 patients consecutively with bladder cancer treated by radical cystectomy from 2008 to 2012 in Shanghai Zhongshan Hospital and Fudan University Shanghai Cancer Center (FUSCC), respectively. The first cohort with 201 patients was treated as training set and the other as validation set. TMAs were created in triplicated from formalin-fixed, paraffin embedded specimens. Immunohistochemistry was performed to assess the expression of B4GALT1 in tumor cores and CD8 in both tumor and peri-tumor cores, and its association between B4GALT1 and the infiltrated CD8+ T cell number, also with clinical outcomes. RESULTS B4GALT1 expression was significantly associated with tumor size (P=0.005 and P=0.014, respectively), T stage (P=0.017 and P=0.004, respectively), OS (P<0.001 and P<0.001, respectively) and PFS (P=0.033 and P=0.034, respectively) in both cohorts. Furthermore, high expression of B4GALT1 was an independent indicator of poor OS (P=0.022 and P=0.017, respectively) in patients with MIBC. The prognostic model containing B4GALT1 showed a better predictive accuracy than the basic models. And the B4GALT1 expression was inverse correlated with the number of peri-tumor infiltrated CD8+ T cell, but not with the number of tumor infiltrated CD8+ T cell. Most importantly, the benefit of adjuvant chemotherapy observed in non-organ confined bladder cancer patients with low B4GALT1 expression was superior to patients with high expression. CONCLUSIONS Our study suggested that B4GALT1 is a potential prognostic biomarker of MIBC, and might be a predictive marker for the patients' selection of adjuvant chemotherapy in high recurrence risk subgroup patients. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e775 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Huyang Xie More articles by this author Yu Zhu More articles by this author Zewei Wang More articles by this author Qiang Fu More articles by this author Jiejie Xu More articles by this author Dingwei Ye More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...
What problem does this paper attempt to address?